The Albanese Government has effectively rejected or obfuscated most of the committee's recommendations, but that does not mean the response has no value or cannot contribute to positive change. Stakeholders must understand the nuance and recognise the real opportunities because these processes never deliver the 'magic bullet'.
A minimalist but entirely predictable response - the opportunities are in the nuance
December 1, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Most Australians want PBS medicine prices frozen or cut, poll finds
October 30, 2026 - - Latest News -
Canberra program shows young women where a future in health could take them
October 30, 2026 - - Latest News -
If only these patients needed a Spoodle, rather than a medicine
October 30, 2026 - - Latest News -
A hearing that provided more evidence of the need for meaningful change
October 29, 2026 - - Latest News -
Biotech sector warns R&D tax changes could drive clinical trials offshore
October 28, 2026 - - Latest News -
Rebates and net spend are the major PBS story of the past decade
October 28, 2026 - - Latest News -
Astellas bets up to US$1.34 billion on Melbourne startup's cancer candidate
October 28, 2026 - - Latest News
